Israeli revolutionary Alzheimer’s treatment to launch Phase 1 trial

The Phase I trial will specifically test ImmunoBrain Checkpoint’s proprietary antibody, IBC-Ab002, which is targeted to enhance the immune system and induce brain repair processes.